422
Participants
Start Date
October 30, 2008
Primary Completion Date
September 1, 2010
Study Completion Date
September 1, 2010
liraglutide
Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
placebo
Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
Novo Nordisk Investigational Site, New York
Novo Nordisk Investigational Site, Endwell
Novo Nordisk Investigational Site, Philadelphia
Novo Nordisk Investigational Site, Philadelphia
Novo Nordisk Investigational Site, Norfolk
Novo Nordisk Investigational Site, Winston-Salem
Novo Nordisk Investigational Site, Wilmington
Novo Nordisk Investigational Site, Charleston
Novo Nordisk Investigational Site, Atlanta
Novo Nordisk Investigational Site, Pembroke Pines
Novo Nordisk Investigational Site, Nashville
Novo Nordisk Investigational Site, Louisville
Novo Nordisk Investigational Site, Madisonville
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Southfield
Novo Nordisk Investigational Site, Butte
Novo Nordisk Investigational Site, St Louis
Novo Nordisk Investigational Site, Dallas
Novo Nordisk Investigational Site, Round Rock
Novo Nordisk Investigational Site, Colorado Springs
Novo Nordisk Investigational Site, Meridian
Novo Nordisk Investigational Site, Peoria
Novo Nordisk Investigational Site, Goodyear
Novo Nordisk Investigational Site, Montclair
Novo Nordisk Investigational Site, Huntington Beach
Novo Nordisk Investigational Site, Hialeah
Novo Nordisk Investigational Site, Winnipeg
Novo Nordisk Investigational Site, Burlington
Novo Nordisk Investigational Site, Hamilton
Novo Nordisk Investigational Site, Sarnia
Novo Nordisk Investigational Site, Laval
Novo Nordisk Investigational Site, Mirabel
Novo Nordisk Investigational Site, Sherbrooke
Novo Nordisk Investigational Site, Trois-Rivières
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Montreal
Lead Sponsor
Novo Nordisk A/S
INDUSTRY